You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Medications for Synthetic Cannabinoid Abuse
SBC: PAFOSPharma, LLC Topic: R41PROJECT SUMMARY ABSTRACT In response to PAthis Phase I STTR proposal will aim at developing pharmacotherapies that can act aslife savermedications to counteract the neurotoxic effects of synthetic cannabinoidsSCsTowards this goalwe will synthesize CB R antagonists with fast onsets of action that can be administered in an emergency roomERsituationThe rationale is based on the successful soft agonis ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
AHTP-comet: development of an automated, high throughput comet assay system
SBC: ENGINEERING RESOURCES GROUP INC Topic: NIEHSPROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction
SBC: IMMUNOCHEM THERAPEUTICS LLC Topic: 102PROJECT SUMMARY Cognitive decline and deterioration of long term cognitive performance are major side effects of CNS cancer treatmentBrain metastases are the most common CNS malignancies and a common cause of morbidity and mortality in aboutof all cancer patients with systemic diseaseaffecting overpatients in the US annuallyAs most systemic chemotherapy agents do not cross the blood brain barriert ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Developing a Scalable Manufacturing Process for an Oral Bacteriophage Product that Prevents Cholera
SBC: PHAGEPRO, INC. Topic: NIAIDPROJECT SUMMARY Cholera is an acute and severe disease caused by the bacterium Vibrio cholerae that is spread primarily through contaminated water sources due to a lack of adequate sanitation infrastructure. The World Health Organization estimates that there are at least 3 million cases globally per year, 40 percent of which are spread through household transmission. Current prevention methods req ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Analytics-Based Platform for Diabetic Retinopathy Care Management
SBC: RETINAL CARE INC Topic: NEIABSTRACT Despite the overefficacy of diabetic retinopathyDRtreatmentit continues to be the leading cause of blindness in working age AmericansOvermillion adults in the US have diabetesOf thesewill develop DR andwill develop vision threatening DRVTDRCurrentlyless than half of all patients with diabetes receive the recommended annual dilated eye exam andof those diagnosed with VTDRonlyundergo timely ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases
SBC: MAKSCIENTIFIC Topic: 400RESEARCH andampRELATEDUnitPROJECT SUMMARY ABSTRACT In response to PAthe aim of this Phase I STTR proposal is to optimize and develop peripherally actingcannabinoidreceptorCB Rneutral antagonists displaying favorable therapeutic profiles for treating diabetic nephropathyDNDN is a chronic diabetic kidney disease and affectstypeand typediabetic patientsIt is characterized by persistent albuminuria an ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis
SBC: OASIS PHARMACEUTICALS, LLC Topic: NHLBIIdiopathic pulmonary fibrosis (IPF), the most common of the interstitial lung diseases, occurs in about 128,000 people, with 48,000 new cases diagnosed annually in the US. The typical clinical course is a progressive fibrotic disease characterized by scarring and `honeycombingandapos; of the lungs causing an irreversible loss of the tissueandapos;s ability to transport oxygen. Co-morbid pulmonary ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of OCF001 for Treatment of Yeast Infections
SBC: Sano Chemicals, Inc. Topic: NIAIDProject Summary Occidiofungins (A-D) are cyclic nonribosomally synthesized antifungal peptides with submicromolar fungicidal activity against a broad spectrum of fungi. Optimization of the production and isolation of occidiofungins from liquid cultures has been performed. The production and isolation of predominantly one analog, called occidiofungin B (OCF001), supports its commercial development ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Star-dots fluorescent nanoparticles for flow cytometry and biomedical imaging
SBC: Nanoscience Solutions, LLC Topic: NIAIDFluorescent nanoparticlesFNPare becoming increasingly popular in biomedical imaging and taggingCompared to molecule based fluorophoresFNP are typically brighter and more photostableThey can be functionalized with more than one tagging moleculeused for the tagging and tracing of specific moleculescellstissuesBrighter fluorescence facilitates more sensitive labelingand in many casesa lower limit of ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
MISSION U: A MULTIMEDIA TRAINING TOOL FOR TREATING INDIVIDUALS WITH CO-OCCURRING MENTAL HEALTH AND SUBSTANCE USE DISORDERS
SBC: PRAXIS, INC. Topic: 350Co-occurring mental health and substance use disorders (COD) are common in the United States and providers have been challenged to provide effective treatments. As a consequence, their clients with COD may experience poor treatment engagement, symptom exacerbation and cycle in and out of emergency services. This is particularly true for underrepresented populations with a COD including individuals ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health